Mouse models of Mdm2 and Mdm4 and their clinical implications

Chinese Journal of Cancer

Volumn 32, Issue 7, 2013, Pages 371-375

  Xiong, Shunbin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Knockin; Knockout; Mdm2 and Mdm4 inhibitors; p53; Transgene

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

APOPTOSIS; CANCER PATIENT; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE ARREST; DIMERIZATION; EMBRYO DEATH; EMBRYO DEVELOPMENT; GENE DELETION; GENE OVEREXPRESSION; GENE TARGETING; HETERODIMERIZATION; HUMAN; KNOCKOUT MOUSE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TISSUE SPECIFICITY; WILD TYPE;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84879817483     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10286     Document Type: Review

References (43)

1. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 2010,330:1340-1344.
2. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res, 2000,60:6788-6793.
3. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 1994,84:3158-3165.
4. Zhou M, Yeager AM, Smith SD, et al. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood, 1995,85:1608-1614.
5. Valentin-Vega YA, Barboza JA, Chau GP, et al. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol, 2007,38:1553-1562.
6. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res, 2009,7:1-11.
7. Duan W, Gao L, Druhan LJ, et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst, 2004,96:1718-1721.
8. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature, 2004,429:86-92.
9. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med, 2004,10:1321-1328.
10. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004,303:844-848.
11. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A, 2008,105:3933-3938.
12. Bernal F, Wade M, Godes M, et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell, 2010,18:411-422.
13. Reed D, Shen Y, Shelat AA, et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem, 2010, 285:10786-10796.
14. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 1995,378:203-206.
15. Jones SN, Roe AE, Donehower LA, et al. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature, 1995,378:206-208.
16. Mendrysa SM, McElwee MK, Michalowski J, et al. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol, 2003,23:462-472.
17. Liu G, Terzian T, Xiong S, et al. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol, 2007,213:360-368.
18. Ringshausen I, O'Shea CC, Finch AJ, et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell, 2006,10:501-514.
19. Migliorini D, Denchi EL, Danovi D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol, 2002,22:5527-5538.
20. Finch RA, Donoviel DB, Potter D, et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res, 2002,62:3221-3225.
21. Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet, 2001,29:92-95.
22. Garcia D, Warr MR, Martins CP, et al. Validation of Mdmx as a therapeutic target for reactivating p53 in tumors. Genes Dev, 2011,25:1746-1757.
23. Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis, 2002,32:145-147.
24. Grier JD, Xiong S, Elizondo-Fraire AC, et al. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol, 2006,26:192-198.
25. Lengner CJ, Steinman HA, Gagnon J, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol, 2006,172:909-921.
26. Kodama T, Takehara T, Hikita H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest, 2011,121:3343-3356.
27. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol, 2010,20:299-309.
28. Boesten LS, Zadelaar SM, De Clercq S, et al. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ, 2006,13:2089-2098.
29. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation, 2007,115:2925-2930.
30. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A, 2006,103:3226-3231.
31. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle, 2004,3:900-904.
32. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol, 2003,23:5113-5121.
33. Pant V, Xiong S, Iwakuma T, et al. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A, 2011,108:11995-12000.
34. Huang L, Yan Z, Liao X, et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A, 2011,108:12001-12006.
35. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res, 1998,26:3453-3459.
36. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res, 2004,2:1-8.
37. Ramos YF, Stad R, Attema J, et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res, 2001,61:1839-1842.
38. Riemenschneider MJ, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res, 1999,59:6091-6096.
39. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature, 2006,444:61-66.
40. Jones SN, Hancock AR, Vogel H, et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A, 1998,95:15608-15612.
41. Xiong S, Pant V, Suh YA, et al. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res, 2010,70:7148-7154.
42. De Clercq S, Gembarska A, Denecker G, et al. Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo. Mol Cell Biol, 2010,30:5394-5405.
43. Wang YV, Wade M, Wong E, et al. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A, 2007,104:12365-12370.